Development of single chain antibodies to P185 tumor antigen

Iranian Red Crescent Medical Journal

Volumn 10, Issue 4, 2008, Pages 298-302

  Nejatollahi, F ^a   Malek Hosseini, Z ^a   Mehrabani, D ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer immunotherapy; Human recombinant antibody; P185; ScFv

Indexed keywords

COAT PROTEIN; DNA; EPITOPE; MESSENGER RNA; PROTEIN P185; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN;

ANTIBODY ENGINEERING; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; DNA FINGERPRINTING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; GENE LIBRARY; GENE OVEREXPRESSION; HUMAN; LYMPHOCYTE; MOLECULAR CLONING; PROTEIN EXPRESSION;

EID: 66149152263     PISSN: 20741804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Pero SC, Shukla GS, Armstrong AL, Peterson D, Fuller SP, Godin K, Kingsley-Richards SL, Weaver DL, Bond J, Krag DN. Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells. Int J Cancer 2004;111(6): 951-60. [PMID: 15300809] doi:10.1002/ ijc.20306
2. Doherty JK, Bond C, Jardim A, Adelman JP, Clinton GM. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci USA 1999;96: 10869-74. [PMID: 10485918] doi:10.1073/pnas.96.19.10869
3. Belimezi MM, Papanastassiou D, Merkouri E, Baxevanis CN, Mamalaki A. Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment. Cancer Immunol Immunother 2006;55:1091-9. [PMID: 16311733] doi:10.1007/s00262-005-0100-z
4. Zhang HT, Wang Q, Greene MI, Murali R. New perspectives on anti-HER2/neu therapeutics. Drug News Perspect 2000;13:325-9. [PMID: 12937653]
5. Loussouarn D, Brunon J, Avet-Loiseau H, Campone M, Mosnier JF. Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study. Hum Pathol 2006;37:415-2. [PMID:16564915] doi:10.1016/ j.humpath.2005.12.020
6. Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p. 369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 2002; 8(5):1014-8. [PMID: 12006513]
7. Dakappagari NK, Lute KD, Rawale S, Steele JT, Allen SD, Phillips G, Reilly RT, Kaumaya PT. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. J Biol Chem 2005;280:54-63. [PMID: 15507452]
8. Scanlan MJ, Jager D. Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res 2001;3:95-8. [PMID:11 250753] doi:10.1186/bcr278
9. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181:2109-17. [PMID:7539040] doi:10.1084/jem.181.6.2109
10. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26. [PMID:11821 453] doi:10.1200/ JCO.20.3.719
11. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. [PMID:11248153] doi:10.1056/NEJM200103153441101
12. Fornier M, Risio M, Van Poznak C, Seidman A. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology 2002; 16: 1340-8. [PMID: 12435204]
13. Emlet DR, Brown KA, Kociban DL, Pollice AA, Smith CA, Ong BB, Shackney SE. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther 2007;6:2664-74. [PMID:17938260] doi:10.1158/ 1535-7163.MCT-07-0079
14. Adamo V, Franchina T, Adamo B, Ferraro G, Rossello R, Maugeri Sacca M, et al. Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study). Ann Oncol 2007;18 Suppl 6:11-5. [PMID:17591801] doi:10.1093/annonc/mdm217
15. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991;222(3):581-97. [PMID: 1748994] doi:10.1016/0022-2836 (91)90498-U
16. Kang AS, Barbas CF, Janda KD, Benkovic SJ, Lerner RA. Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. Proc Natl Acad Sci USA 1991; 88(10):4363-6. [PMID: 1903540] doi:10.1073/ pnas.88.10.4363
17. Burnie JP, al-Wardi EJ, Williamson P, Matthews RC, Webb K, David T. Defining potential targets for immunotherapy in Burkholderia cepacia infection. FEMS Immunol Med Microbiol 1995;10:157-64. [PMID: 7536517] doi:10.1111/j.1574-695X.1995.tb00026.x
18. Staneloudi C, Smith KA, Hudson R, Malatesti N, Savoie H, Boyle RW, Greenman JDevelopment and characterization of novel photosensitizer: scFv conjugates for use in photodynamic therapy of cancer. Immunology 2007;120:512-7. [PM ID:17343613] doi:10.1111/ j.1365-2567.2006.02522.x
19. McWhirter JR, Kretz-Rommel A, Saven A, Maruyama T, Potter KN, Mockridge CI, Ravey EP, Qin F, Bowdish KS. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 2006;103:1041-6. doi:10.1073/pnas.0510081103
20. Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD. Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. J Mol Med 2007;85:1113-23. [PMID:17554518] doi:10.1007/ s00109-007-0208-z
21. Knutson KL, Schiffman K, Disis ML. Immunization with a HER2/neu helper peptide vaccine generates HER2/neu CD8 T-cell immunity in cancer patients. J Clin Inv 2001; 107:477-84. [PMID:11181647] doi:10.1172/JCI11752
22. Ishihara Y, Harada M, Azuma K, Tamura M, Shomura H, Fujii T, Itoh K, Shichijo S. HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients. Int J Oncol 2004;24:967-75. [PMID: 15010837]
23. Perez SA, Sotiropoulou PA, Sotiriadou NN, Mamalaki A, Gritzapis AD, Echner H, Voelter W, Pawelec G, Papamichail M, Baxevanis CN. HER-2/ neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones. Cancer Immunol Immunother 2002;50:615-24. [PMID: 11807625] doi:10.1007/s002620100225
24. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002; 62(1):209-43. [PMID:11 7901 61] doi:10.2165/ 00003495-200262010-00008
25. Yeon CH, Pegram MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 2005;23(5): 391-409. [PMID:16133791] doi:10.1007/s10637-005-2899-8